Evidence map›Paper›PMID 34662190›Full record

SynthesisAntimicrobial agents and chemotherapy2022

Secondary Analysis of a Systematic Review: Are Antifungal Noninferiority Trials at Risk of Eroding Effectiveness Because of Biocreep?

Adam S Komorowski, Anthony D Bai, Anna Cvetkovic, Omar Mourad, Carson K L Lo, Xena X Li, Vaibhav Mokashi, Aidan Findlater, D Brody Duncan, Charlotte Fuller and 4 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adam S KomorowskiDivision of Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0003-2101-7701
Anthony D BaiClinician-Investigator Program, Faculty of Health Sciences, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0003-0448-9934
Anna CvetkovicDivision of Infectious Diseases, Department of Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0003-0431-3074
Omar MouradDivision of Infectious Diseases, Department of Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.
Carson K L LoDivision of Infectious Diseases, Department of Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0002-1620-2868
Xena X LiDivision of Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0003-1510-6310
Vaibhav MokashiDivision of Infectious Diseases, Department of Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0002-3775-9745
Aidan FindlaterDivision of Infectious Diseases, Department of Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0003-4698-7536
D Brody DuncanDivision of Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0002-7634-6484
Charlotte FullerDivision of Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.
Daniela L LetoDivision of Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.
Deborah YamamuraDivision of Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.
Dominik MertzDivision of Infectious Diseases, Department of Medicine, McMaster Universitygrid.25073.33, Hamilton, Ontario, Canada.ORCID 0000-0003-4337-1613
McMaster Infectious Diseases Fellow Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noninferiority randomized controlled trial (RCT) effectiveness may erode when results favor the active control over time and when a decreasingly effective control arm is used in serial trials. We analyzed 32 antifungal noninferiority RCTs (NI-RCTs) for these scenarios in this secondary analysis of a systematic review. Our exploratory analysis suggests that the erosion risk in the effectiveness of antifungal noninferiority trials is uncommon. Findings are limited by small sample size and overall risk of bias.

Indexed as

Antifungal AgentsRandomized Controlled Trials as TopicAntifungal Agentsantifungal agentsanti-infective agentsbiocreepnoninferiority trialssystematic review

Identifiers

PMID34662190
PMCPMC8765287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.